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Pluripotent stem cells (PSCs) are defined by their self-renewal potential, which permits
their unlimited propagation, and their pluripotency, being able to generate cell of the
three embryonic lineages. These properties render PSCs a valuable tool for both basic
and medical research. To induce and stabilize the pluripotent state, complex circuitries
involving signaling pathways, transcription regulators and epigenetic mechanisms
converge on a core transcriptional regulatory network of PSCs, thus determining their cell
identity. Among the transcription factors, MYC represents a central hub, whichmodulates
and integrates multiple mechanisms involved both in the maintenance of pluripotency
and in cell reprogramming. Indeed, it instructs the PSC-specific cell cycle, metabolism
and epigenetic landscape, contributes to limit exit from pluripotency and modulates
signaling cascades affecting the PSC identity. Moreover, MYC extends its regulation on
pluripotency by controlling PSC-specific non-coding RNAs. In this report, we review the
MYC-controlled networks, which support the pluripotent state and discuss how their
perturbation could affect cell identity. We further discuss recent finding demonstrating a
central role of MYC in triggering epigenetic memory in PSCs, which depends on the
establishment of a WNT-centered self-reinforcing circuit. Finally, we comment on the
therapeutic implications of the role of MYC in affecting PSCs. Indeed, PSCs are used
for both disease and cancer modeling and to derive cells for regenerative medicine. For
these reasons, unraveling the MYC-mediated mechanism in those cells is fundamental
to exploit their full potential and to identify therapeutic targets.
Keywords: MYC, pluripotent stem cells, transcription regulatory networks, epigenetics, signaling pathways,
epigenetic memory, cancer
PLURIPOTENT STEM CELLS IDENTITY
Pluripotent stem cells (PSCs) possess two defining properties: they are able to indefinitely self-
renew, thus maintaining their cell identity after cell division, and they are pluripotent, having the
potential to differentiate toward all cell lineages of the organism. Those properties have made PSCs
an attractive tool in many research areas such as developmental studies (Keller, 2005; Niwa, 2010),
regenerative medicine (Cohen and Melton, 2011; Wu and Hochedlinger, 2011; Cherry and Daley,
2012), drugs discovery (Grskovic et al., 2011; Avior et al., 2016), disease and cancer modeling (Zhu
et al., 2011; Bellin et al., 2012; Robinton and Daley, 2012; Kim and Zaret, 2015; Laplane et al., 2015;
Zeltner and Studer, 2015; Avior et al., 2016).
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In vivo, PSCs are a transient cell population emerging
approximately at embryonic day 3.5 (E3.5) in mouse embryos,
and are confined to the inner cell mass (ICM) of the blastocyst,
which will further differentiate giving rise to all embryonic tissues
(Cockburn and Rossant, 2010). Despite this transient existence
during embryogenesis, many different PSCs have been derived
and indefinitely maintained in vitro, including embryonic stem
cells (ESCs) derived from the ICM (Evans and Kaufman, 1981;
Martin, 1981; Thomson et al., 1998), post-implantation epiblast-
derived stem cells (EpiSCs) (Brons et al., 2007; Tesar et al., 2007),
and induced PSCs (iPSCs), obtained through the reprogramming
of somatic cells (Takahashi and Yamanaka, 2006; Takahashi et al.,
2007).
The in vitro derivation and maintenance of all those
PSCs is strictly dependent on provided extrinsic signals, as
PSCs continuously balance their self-renewal and differentiation
potential in response to environmental cues, which are integrated
with the epigenetic machinery and the transcriptional regulatory
network (TRN), governing cell identity (Chen et al., 2008; Ying
et al., 2008; Ng and Surani, 2011; Clevers et al., 2014; Fagnocchi
et al., 2016b). Thus, to identify the molecular mechanisms
which are responsible for pluripotency is fundamental to fully
exploit the potential of PSCs. Our major understanding of the
TRN governing pluripotency comes from studies on mouse
ESCs (mESCs), which lead to the identification of the core
transcription factors (TFs) required for their cell identity:
Oct4 (also known as Pou5f1), Sox2 and Nanog (collectively
known as OSN). Oct4 and Nanog were identified as core TFs
of pluripotency due to their specific expression during early
development and in ESCs, and were demonstrated to affect both
the establishment and the maintenance of a stable pluripotent
state both in vivo and in vitro (Nichols et al., 1998; Avilion
et al., 2003; Chambers et al., 2003; Mitsui et al., 2003; Loh
et al., 2006). Even if ESCs can be propagated in absence of
Nanog and it is expressed at low levels in mouse EpiSCs, it
is required for the formation of the ICM in vivo and widely
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co-localize with Oct4 and Sox2 in ESCs (Chambers et al.,
2007; Marson et al., 2008; Silva et al., 2009). Oct4 functions as
a heterodimer with Sox2 and they act sinergically, activating
distal regulatory elements which control multiple pluripotency
factors (Avilion et al., 2003; Masui et al., 2007). Importantly,
mapped OSN targets show extensive overlap between mESCs
and human ESCs (hESCs), pointing toward the existence of a
conserved core TRN (Boyer et al., 2005; Loh et al., 2006). The
OSN core positively regulates their own promoters, generating
an interconnected auto-regulatory loop and exerts its role by
concomitantly sustaining pluripotency and self-renewal factors,
while restricting differentiation by repressing lineage-specificing
TFs. When OSN are expressed at optimal levels, ESCs are stably
maintained, while their perturbation leads to exit pluripotency
and cell differentiation (Chambers et al., 2007; Toyooka et al.,
2008; Karwacki-Neisius et al., 2013). Of note, an extended TRN
have been elucidated in mESCs, comprising multiple TFs and
downstream effectors of signaling pathways, which influence the
ability of OSN to sustain PSCs identity (e.g.,: Klf4, Klf2, Dax1,
Nac1, Zfp281, Essrb, Sall4, Tbx3, Prdm14, Stat3, Smad1, and
Tcf3) (Niwa et al., 1998; Chen et al., 2008; Cole et al., 2008; Kim
et al., 2008; Ng and Surani, 2011; Fagnocchi et al., 2016b).
Among the TFs which have been shown to play a crucial
role for PSCs identity, MYC family members MYC and MYCN
modulate both the establishment and the maintenance of
PSCs (Chappell and Dalton, 2013). Indeed, co-deletion of both
myc and mycn disrupts the maintenance of ESCs and iPSCs,
while favoring their differentiation (Cartwright et al., 2005;
Smith et al., 2010; Varlakhanova et al., 2010; Fagnocchi et al.,
2016a). In addition MYC is essential to efficiently generate
fully reprogrammed mouse and human iPSC, by enhancing
OSN activity in the early steps of reprogramming (Takahashi
and Yamanaka, 2006; Takahashi et al., 2007; Soufi et al.,
2012). In this review, we will provide a brief overview on
MYC transcription factors and then focus on the multiple
mechanisms through which they can favor the pluripotent
state, by integrating their transcriptional regulation activity with
signaling pathways and epigenetic players. Finally, we will discuss
the potential therapeutic implications of the described MYC-
dependent regulatory networks.
MYC TRANSCRIPTION FACTORS
MYC (also called c-MYC) was first identified more than 30
years ago as a cellular homolog of the v-myc oncogene of
the avian myelocytomatosis retrovirus (Hayward et al., 1981;
Vennstrom et al., 1982). It belongs to a basic helix–loop–
helix leucine-zipper (bHLH-LZ) family of TFs comprising also
MYCN andMYCL, which are evolutionarily conserved and share
significant protein sequence similarities. MYC proteins comprise
an N-terminal transactivation domain (TAD), several conserved
motifs named MYC boxes (MBI, II, III, and IV), which have
been described to be important for MYC multiple activities, a
nuclear localization sequence (NLS) and a C-terminal region
with the bHLH and the LZ domains, fundamental in mediating
DNA binding and also protein-protein interactions. (Cole and
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Cowling, 2008). Generally MYC requires to heterodimerize with
the bHLH-LZ protein MAX in order to bind the canonical
E-box elements (CACGTG) or other non-canonical variants
(CANNTG) (Blackwell et al., 1990, 1993; Blackwood and
Eisenman, 1991; Solomon et al., 1993; Lin et al., 2012). MYC
binding sites frequently correlate with active promoters, which
are enriched for DNase I hypersensitive sites, active chromatin
marks and CpG islands (Fernandez et al., 2003; Guccione et al.,
2006; Zeller et al., 2006; Kim et al., 2008). This chromatin patter is
well in line with the finding that MYC cannot act as a pioneer TF
but rather requires an open chromatin context to access DNA,
as found in iPSC (Soufi et al., 2012). More recently, ChIP-seq
data demonstrated that MYC also localizes at distal regulatory
elements, in a cell type and concentration-dependent manner,
binding enhancer regions when highly expressed (Lin et al., 2012;
Nie et al., 2012; Sabo et al., 2014; Walz et al., 2014).
At the functional level, MYC is a relatively weak
transcriptional modulator, leading to small changes of its target
genes. It exerts its functions by interplaying with a large set of
other TFs, co-activators or by recruiting chromatinmodifiers (Tu
et al., 2015). MYC binding has been predominantly associated
with activation of its target genes, accomplished through the
recruitment of chromatin modifying factors (such as histone
acetyltransferases) or by directly interacting with transcriptional
co-activators (such as Mediator and P-TEFb complex), finally
leading to release of stalled RNA polymerase II complex and
to transcriptional elongation (Cole and Nikiforov, 2006; Zippo
et al., 2007, 2009). Nonetheless, different mechanisms through
which MYC mediates transcriptional repression have also
been described, among which the best documented is the
interaction with the transcription factor MIZ-1 (Seoane et al.,
2001; Staller et al., 2001; Herkert and Eilers, 2010; Walz et al.,
2014). Recently, the selective activity of MYC to transcriptionally
modulate its targets has been challenged by the finding that
it can eventually invade all active elements in the genome,
mediating or potentiating their transcription, thus acting as a
general “amplifier” (Lin et al., 2012; Nie et al., 2012). However,
this phenomenon strictly depends on both the cell type and the
level of expression of MYC, it does not account for genes that are
repressed by MYC and it has been proposed as a secondary effect
of MYC-mediated modulation of specific targets (Kress et al.,
2015). In spite of the large amount of both RNA and chromatin
profiling available, a unified model explaining the mechanism of
MYC in modulating transcription is, indeed, still not available.
Under physiological conditions, MYC proteins have well-
established pivotal roles in influencing basic cellular processes
such as cell-cycle progression, cell proliferation and growth,
cell size, energy metabolism, DNA replication, RNA production,
differentiation and apoptosis (Eilers and Eisenman, 2008;
Van Riggelen et al., 2010; Dang, 2013). For this reason,
during adult tissues homeostasis, MYC expression is finely
regulated by transcriptional, post-transcriptional and post-
translational regulatory mechanisms (Levens, 2010; Farrell and
Sears, 2014) and typically maintained at low levels or restricted
to regenerating and proliferating cells (such as in epidermis and
gut). On the other hand, being such a critic hub for cell regulatory
networks, its over-expression is a hallmark associated to up to the
70% of all human cancers (Dang, 2012; Ciriello et al., 2013; Gabay
et al., 2014). Both MYC and MYCN have a well-documented
transforming capacity of cells in vitro, while MYCL is deficient
in oncogenic potential (Land et al., 1983; Barrett et al., 1992).
During tumorigenesis, over-expression ofMYC is achieved either
directly through gene amplification or translocation, or indirectly
through mis-regulation of the many signaling pathways which
are themselves targets of oncogenic mutations and regulate its
expression under physiological conditions (e.g., Ras, Wnt, and
Notch) (Dang, 2012). In addition to drive cancer initiation,
MYC is also responsible for its maintenance: in several MYC-
driven mouse tumor models, blocking MYC activity elicits
tumor regression by promoting growth arrest and apoptosis
and inducing cell differentiation, such as in sarcoma and
hepatocellular cancer (Felsher and Bishop, 1999; Jain et al., 2002;
Pelengaris et al., 2002; Shachaf et al., 2004). Finally, MYC seems
also to play a crucial role in tumors driven by other oncogenes
(e.g., RAS and SV40 T antigen), as targeting endogenous MYC
leads to their regression (Soucek et al., 2008; Sodir et al., 2011).
Altogether these evidences underline the potential of targeting
MYC and its modulated targets for cancer therapy.
ROLE OF MYC IN THE MAINTENANCE OF
PSCS
MYC-mediated maintenance of PSCs relies on its central
role in cellular complex regulatory networks, integrating
environmental signaling pathways with transcriptional and
epigenetic modulations (Figure 1). In the following sections we
will discuss in details the various mechanisms through which
MYC sustains PSC identity.
MYC TFs in Early Embryonic Development
The first evidence supporting the implication of MYC TFs
in sustaining pluripotency is represented by their role during
embryonic development. At the pre- and early post-implantation
embryonic stages, MYC and MYCN share the same expression
profiles and are functionally redundant, as MYCN can substitute
MYC throughout development, leading to viable and fertile
adult mice (Zimmerman et al., 1986; Malynn et al., 2000). As
a consequence, single knock-out mutations on either myc or
mycn do not cause developmental defects before gastrulation.
In addition, pluripotent and self-renewing ESCs can be derived
from ICM lacking either myc or mycn. At mid-gestation
stage, instead, their expression starts to diversify, leading to
abnormalities:myc null embryos arrest at E10.5, showing growth,
cardiac, neural, hematopoietic and vascular defects, and delay or
failure in turning of the embryo (Davis et al., 1993; Trumpp et al.,
2001; Baudino et al., 2002; Dubois et al., 2008); mycn knock-out
embryos die between E10.5 and E12.5, exhibiting aberrations in
limb bud, visceral organs (lung, stomach, liver, and heart) and the
central/peripheral nervous systems (Charron et al., 1992; Stanton
et al., 1992; Sawai et al., 1993). On the contrary, MYCL is totally
dispensable during the whole embryogenesis and mycl−/− mice,
expressing MYC or MYCN, are viable without abnormalities
(Hatton et al., 1996).
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FIGURE 1 | MYC regulatory networks in pluripotent stem cells. Schematic representation of part of the molecular mechanisms through which MYC affects the
PSC identity. MYC supports the pluripotent state by favoring both the typical cell cycle structure and metabolism of PSCs. In addition, it contributes to repress
developmental genes, in collaboration with MIZ-1 and PRC2. MYC further extends its regulatory action by integrating a complex network of ncRNAs, which finally
affects all aspects of the PSC life. Moreover, by interacting with chromatin modifiers and remodelers, MYC controls the epigenetic state of PSCs. Finally, it is also a
downstream effector of the LIF pathway and involved in modulating both the MAPK/ERK and the WNT signaling, which converge on the core of PSCs. For detailed
description see the text. Solid green and red arrows indicate a MYC-mediated positive or negative regulation of nearby genes, respectively. Dotted green and red
arrows are used to indicate the integration of multiple roles of MYC, which can either sustain or counteract the pluripotent state, respectively. Solid black arrows and
flat lines indicate activation or repression, respectively. Red crosses indicate lack of transcription of reported genes.
In spite of the absence of defects related to myc or mycn
single null mutants, two key works demonstrated that the
expression of at least one of the two genes is mandatory
during murine early embryonic development (Smith et al.,
2010; Varlakhanova et al., 2010). Concomitant disruption
of myc and mycn triggers spontaneous differentiation of
ESCs and iPSCs toward primitive endoderm and mesoderm,
and embryos injected with ESCs lacking both MYC TFs
predominantly failed to generate chimeras or survived
only during the early development until mid-gestation,
with severe defects. Importantly, re-expression of either
myc or mycn was sufficient to restore PSCs identity,
while MYCL failed to complement the double knock-
out defects. Likewise, single loss of either myc or mycn
is inconsequential in hematopoietic stem cells, but their
concurrent deletion is lethal (Laurenti et al., 2008). These
evidences support the idea that MYC and MYCN are
redundant but essential to determine the PSCs identity
during pre-implantation stages of embryogenesis, when the
ESCs of the ICM are established, whereas MYCL, although
expressed in multiple organs during embryo development, is
dispensable.
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The MYC Module and the Regulatory
Networks of PSCs
In the last decade, the circuitry regulating PSC identity has been
deeply investigated by means of next generation sequencing, in
order to identify the genomic localization of functionally relevant
TFs and the transcriptional outcome of their binding (Boyer et al.,
2005; Loh et al., 2006; Chen et al., 2008; Cole et al., 2008; Kim
et al., 2008, 2010). These analyses were mainly performed in
murine ESCs and led to the possibility to simplify their complex
regulatory networks by breaking them up into distinct units, also
called “modules” (Kim et al., 2010). Three units were defined
in mESCs, according to the co-binding of selected factors: The
core, the polycomb and the MYC modules. As stated above,
the TFs belonging to the core module comprises not only the
proto-typical OSN, but also other TFs and terminal components
of signaling pathways (Ng and Surani, 2011; Fagnocchi et al.,
2016b). The concomitant binding of multiple core TFs on
both promoters and enhancers leads to the transcriptional
activation of hundreds of target genes, whose expression is
required for ESCs maintenance but then get turned off upon
cell lineage commitment (Chen et al., 2008; Kim et al., 2008).
On the contrary, the polycomb module comprises targets of the
polycomb repressive complex 1 (PRC1) and PRC2, which include
differentiation- and development-related genes (Bernstein et al.,
2006; Boyer et al., 2006; Lee et al., 2006). Importantly, there is
almost no overlap between the core and the polycomb modules,
as they are involved in different functions.
The MYC module was first defined in ESCs as the common
targets of MYC, MYCN, and other factors (such as MAX,
DMAP1, ZFX, E2F1, E2F4, TRIM28, and CNOT) and comprised
over 500 genes, which were not shared with neither the core
nor the polycomb modules (Chen et al., 2008; Hu et al., 2009;
Kim et al., 2010). Subsequent analysis on multiple genome
wide binding studies showed that MYC binds as much as 8000
targets in ESCs, which are, indeed, clearly distinct from those
regulated by either core TFs or PRC1/2 (Smith et al., 2011). This
suggests that the global function of MYC in supporting PSCs
identity is not solely relying on its direct binding and modulation
of well-established pluripotency or lineage specification genes,
but rather on its central role as integrator of multiple gene
networks, which finally converge onto and influence the core
module. In fact, this “enlarged MYC module” comprises genes
related to functions distinctly important for the maintenance
of self-renewal and pluripotency, such as cell-cycle progression,
cell growth and metabolic regulation (Kim et al., 2010; Smith
et al., 2011). Importantly, functionally relevant exceptions to
this general activity of MYC have been described: for example
MYC binds and regulates the genes coding for both SOX2 and
the endoderm master regulator GATA6, thus directly affecting
the core TRN and lineage differentiation, respectively (Lin
et al., 2009b; Smith et al., 2010). Furthermore, MYC affects
pluripotency by transcriptionally regulating different clusters
of micro RNAs (miRNAs) and inhibits cell differentiation by
directly and indirectly modulating developmental related genes
and PRC1/2 components (Lin et al., 2009b; Smith and Dalton,
2010; Neri et al., 2012; Fagnocchi et al., 2016a). Finally, the
role of MYC as a central integrator of multiple circuits in PSCs
is underlined by its connection with epigenetic players and
signaling pathway components, both influencing the pluripotent
core module (Chen et al., 2008; Smith andDalton, 2010; Chappell
and Dalton, 2013; Fagnocchi et al., 2016a). Interestingly, the
MYC module was also found to be highly expressed in cancer
cells and to be predictive of cancer outcomes (Kim et al., 2010),
emphasizing the potential therapeutic implications of unraveling
the MYC-mediated regulatory circuitry in PSCs.
MYC and Cell Cycle Control
PSCs posses peculiar cell cycle duration time and structure, which
differ to the ones of committed somatic cells (Figure 1, upper
left panel). During embryogenesis, PSCs of the pre- and early
post-implantation stages divide at unusually rapid rates (with
an estimated generation time as brief as 4.4 h), to support the
expansion in cell number of the developing embryo. Those rapid
cell cycles comprise truncated G1/G2 gap phases and 50–60%
of their time consists in DNA replication (S phase), which is
alternated with rounds of chromosome segregation (M phase).
On the contrary, after the first cell fate commitment during
gastrulation, cell cycle is restructured and dilated to 16 h or more.
At this time of development, most cells spend the majority of
their time in extended G1/G2 phases (Snow, 1977; Mac Auley
et al., 1993; Power and Tam, 1993; Stead et al., 2002; Faast
et al., 2004). Importantly, the peculiar cell cycle pattern occurring
within the ICM is recapitulated by in vitro cultured PSCs and
is conserved among different species. (Stead et al., 2002; White
et al., 2005; Fluckiger et al., 2006; Tesar et al., 2007).
The molecular mechanisms underpinning these unusual cell
cycles have been investigated in mESCs. These studies showed
that cyclin-dependent kinases (CDKs) are constitutively active
and expressed to significantly elevated levels in mESCs with
respect to committed cells, where their expression become cell
cycle regulated and oscillates in a strictly periodic manner
(Stead et al., 2002; Faast et al., 2004). As a consequence, the
retinoblastoma tumor suppressor (RB) is constantly inactiveted
due to its CDKs-mediated hyper-phosphorylation, thereby
the major G1 checkpoint (the R-point) is lost and cell
division is mitogen-independent (Savatier et al., 1994). In
addition, CDK inhibitory molecules (CDKIs) are also not
expressed in mESCs, supporting constitutive activity of CDK
and rapid cell divisions (Faast et al., 2004; White et al.,
2005). Despite sharing a similar cell cycle pattern with
mESCs, hESCs possess slower timing of division and display
cycle-dependent expression of CDKs and regulation of RB,
and increased level of CDKIs, similarly to differentiated
somatic cells. Thus, alternative molecular regulation of cell
cycle must exist in hESCs, which have been shown to
require the activity of CDK1/2 (Neganova et al., 2009, 2011,
2014).
The central role of MYC in affecting the timing and pattern
of cell cycle in PSCs is underlined during early embryogenesis.
Upon the first commitment of PSCs, MYC levels collapse and cell
cycle structure acquires the typical somatic cell characteristics.
Accordingly, genome wide binding analysis demonstrates that
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cell cycle regulators, such as cyclins, CDKs and E2F TFs are
widely enriched among MYC targets in PSCs (Kidder et al.,
2008; Kim et al., 2008; Smith et al., 2011; Nie et al., 2012;
Bretones et al., 2015). Indeed, elevated MYC activity accelerates
the progression toward G1 and increases the cell division rate
and cell proliferation. On the contrary, concomitant myc and
mycn null ESC mutants possess shortened S and lengthened
G1 phases (Smith et al., 2010). Mechanistically, MYC can
either directly activate transcription of several cyclins and CDKs
(such as cyclin A, B1, D1/2, and E2, and CDK1, 4, 6, and
7 in PSCs) or indirectly modulate their protein stability by
regulating CDK activating kinases (CAK) and CDC25 family
phosphatases (Smith and Dalton, 2010; Bretones et al., 2015).
In addition, MYC suppresses CDKIs, such as p21Cip1, p27Kip1
and INK4 family members, by either antagonizing MIZ-1,
recruiting chromatin modifiers or transcriptionally modulating
other regulators (Brenner et al., 2005; Bretones et al., 2015).
Moreover, both MYC and MYCN have been demonstrated to
physically interact with RB and favor the loss of the R-point
cell cycle arrest (Rustgi et al., 1991; Goodrich and Lee, 1992).
Finally, MYC extends its control on cell cycle regulators by
modulating the expression of miRNAs clusters, as discussed
below in details. This role of MYC in sustaining PSCs specific
cell cycle structure is relevant to facilitate their proliferation and
maintain their long term identity. Indeed, cells preferentially
initiate differentiation from G1 phase, suggesting that short G1
would limit the differentiation potential of PSCs, by impeding
the complex chromatin remodeling required to exit pluripotency
(Filipczyk et al., 2007; Singh and Dalton, 2009; Sela et al.,
2012; Pauklin and Vallier, 2013; Dalton, 2015). Importantly,
PSC cell cycle peculiar traits are reminiscent of tumor cells,
in which cell cycle is deregulated independently from extrinsic
mitogenes.
MYC and Metabolic Regulation
As it happens for cell cycle, the metabolism of PSCs also
differs considerably from that of committed cells, due to
different availability of oxygen and substrates which those cells
experience. Somatic cells normally generate energy through
carbon sources oxidation and production of reducing agents
which triggers the electron transport chain (ETC) and leads
to oxidative phosphorylation (Oxphos) (Figure 1, upper central
panel). On the contrary, PSCs possess less mitochondrial content
than differentiated counterparts and shift their metabolism to
aerobic glycolysis, reminding theWarburg effect typical of highly
proliferating tumor cells (Warburg, 1956; Van Blerkom, 2009;
Moussaieff et al., 2015a). Despite the fact that PSCs mainly
rely on glycolysis to produce energy (Zhang et al., 2012),
different state of pluripotency are characterized by the use
of different metabolic pathways. PSCs from the ICM at pre-
implantation stage produce energy by using mainly Oxphos
rather than glycolysis, and are recapitulated in vitro by mESCs.
On the contrary, immediately after implantation, the embryo
is inefficiently vascularized and oxygen availability is limited,
therefore energy production relies mainly on glycolysis, similarly
to the metabolic state of murine EpiSCs and hESCs (Leese,
2012; Ryall et al., 2015). Finally, recently derived naïve hESCs,
resembling human ICM cells, exhibit an even higher glycolytic
flux accompanied by Oxphos (Carbognin et al., 2016; Gu
et al., 2016). The reason why different PSCs utilize diverse
metabolic pathways is still debated. Importantly, recent findings
point toward the idea that cellular metabolism is not only
a mere consequence of the cellular environment but rather
is an active mechanism affecting PSCs identity in multiple
ways. In addition to generating energy, metabolism supports
PSCs identity by providing both the molecular intermediates
required to sustain rapid cellular divisions and growth (Vander
Heiden et al., 2009; Lunt and Vander Heiden, 2011) and
metabolites influencing their epigenome (Shyh-Chang et al.,
2013; Shiraki et al., 2014; Carey et al., 2015; Moussaieff et al.,
2015a,b).
In this sense, the well-documented role of MYC inmodulating
metabolic related enzymes, energy production and biomass
accumulation assume particular relevance for its ability to
support PSCs identity. MYC regulates the glucose metabolism,
by stimulating virtually all genes involved in both glycolysis and
glutaminolysis, it favors the synthesis of nucleotides, proteins
and lipids, thus supporting cell growth and proliferation and,
finally, it is involved in mitochondrial and ribosomal biogenesis
(Dang, 2013; Stine et al., 2015). Recent evidences underline the
importance of MYC in regulating the glycolitic metabolism of
both mouse and human ESCs (Cao et al., 2015; Gu et al., 2016).
Cao et al. (2015) demonstrated that, when MBD2-mediated
repression of MYC is alleviated by the miR-290 cluster of
miRNAs, it directly binds to the promoter of two key relevant
glycolytic enzymes, namely PKM2 and LDHA, activating their
expression and enhancing the glycolytic metabolic switch of
mESCs. Accordinglymyc−/− mESCs show diminished glycolityc
signature. The samemolecularmechanism seems to be conserved
in humans and favors the reprogramming of human fibroblasts.
Gu et al. (2016), instead, showed that an increased glycolytic
flux, functionally relevant to support the PSC state, occurs
during the transition from naïve to primed hESCs and this
correlates with augmented MYC transcriptional activity and
elevated levels of nuclear MYCN. In particular, MYC-driven
glycolysis depends on MCT1, a monocarboxylates membrane
transporter. In accordance with this, chemical inhibition of
either MYCN or MCT1 results in decreased proliferation of
naïve hESCs. Furthermore, in addition to directly modulating
the metabolism, MYC is also hard-wired into miRNAs networks
affecting metabolic pathways, as discussed below. Finally,
several recent works demonstrate how metabolic intermediates,
such as α-ketoglutarate (α-KG), S-adenosylmethionine (SAM),
acetyl-coenzyme A (CoA), nicotinamide adenine dinucleotide
(NAD), and flavin adenine dinucleotide (FAD) influence
histone acetylation and DNA/histone methylation in PSCs,
thus regulating their maintenance or differentiation (Shyh-
Chang et al., 2013; Shiraki et al., 2014; Carey et al.,
2015; Ryall et al., 2015; Moussaieff et al., 2015a,b). MYC-
mediated modulation of processes such as glycolysis and
glutaminolysis, which alters the availability of α-KG and CoA,
suggests that it may also affect the epigenome of PSCs as a
consequence, even though this hypothesis has to be formally
proven yet.
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MYC Regulation of the Differentiation
Potential of PSCs
PSCs identity depends on the continuous balance between
their self-renewal and differentiation potentials. While the core
TFs reinforce the expression of pluripotency genes, they also
contribute to repress lineage-specific regulators, thus preventing
the exit from the pluripotent state. OSN bind to and repress
developmental-related genes in combination with repressive
chromatin modifiers, such as SETDB1 and polycomb group
(PcG) proteins, in both mouse and human ESCs (Boyer et al.,
2006; Bracken et al., 2006; Lee et al., 2006; Young, 2011).
Consequently, the loss of OSN-mediated repression rapidly leads
to induction of developmental genes and to lineage commitment
(Bernstein et al., 2006; Mikkelsen et al., 2007; Pan et al., 2007;
Zhao et al., 2007).
Similarly, MYC TFs do not maintain PSCs identity
only by regulating cell cycle, metabolic genes and cell
growth/proliferation, as discussed above, but also by inhibiting
PSCs differentiation, as demonstrated by several lines of evidence
(Figure 1, lower right panel). In 2010, Smith and colleagues
demonstrated that the simultaneous double knock-out of both
myc and mycn (dKO) in either mESCs or iPSCs results in their
differentiation toward primitive endoderm (Smith et al., 2010).
This was attributed to the MYC-mediated repression of GATA6,
a master regulator of primitive endoderm lineage commitment
(Fujikura et al., 2002). Importantly, re-expression of either
myc or mycn in the dKO background was sufficient to restore
pluripotency, suggesting that the two TFs act redundantly
in repressing GATA6 in PSCs. In addition to GATA6, MYC
was also found to bind HES1 and transcriptionally repress
FOXA2 and SOX17, other important primitive endoderm
markers, while, in another report, it was demonstrated to limit
hematopoietic differentiation, by repressing lineage-specific
transcriptional activators and differentiation markers (Smith
et al., 2010; Varlakhanova et al., 2010). These evidences suggest
a more broad activity of MYC in regulating the differentiation
potential of PSCs. Accordingly, MYC acts coordinately with
MIZ-1 in suppressing differentiation of hESCs, by targeting
and repressing a broad range of developmental related genes,
including HOX clusters. MYC-mediated repression is less
characterized compared to its positive regulatory activity,
nonetheless, it is known that MYC is able to bind to MIZ-1
targets and inhibit its transcriptional activation. In addition,
the MYC/MIZ-1 complex acts as a repressor by also recruiting
histone deacetylases (HDACs) and DNA methyltransferases
(DNMTs), which promote gene silencing (Herkert and Eilers,
2010). In hESCs, ∼200 genes are co-bound by MYC/MIZ-1
comprising HOX and genes involved in neural and muscle
differentiation, and at least 36 HOX genes were proven to
be transcriptionally down-regulated upon MYC disruption
(Varlakhanova et al., 2011). Importantly, the MYC/MIZ-1
co-bound developmental genes are enriched in H3K27me3
histone mark, suggesting a potential link between MYC and
PcG in PSCs. In line with this hypothesis, genome wide analysis
reveals that ∼10% of MYC targets in mESCs are shared with the
PRC2 protein SUZ12, leading to modulation of HOX, ectoderm
and neural development-related genes (Lin et al., 2009b). More
recently, we aimed to discern the functional roles of MYC in
sustaining PSCs identity, by comparing mESCs grown in their
standard culture medium, containing leukemia inhibitory factor
(LIF) and serum, with cells grown solely in MYC-dependency
(Fagnocchi et al., 2016a). To this end, we used mESCs expressing
a MYCT58A-estrogen receptor (MYC-ER) fusion protein,
activated by 4-hydroxytamoxifenm (OHT) (Cartwright et al.,
2005; Fagnocchi et al., 2016a). Importantly, we found that
MYC down-regulates developmental-related genes involved in
multi-lineage commitment which are targeted by PRC2 and/or
PRC1. Almost half of total genes down-regulated by MYC in
mESCs correlate with genes repressed by PRC2, and, for a subset
of those genes (such as Dkk1, Sfrp1, Sfrp5, and Apcdd1) we
demonstrated the direct role of MYC in recruiting the PRC2
complex on their promoters to mediate their transcriptional
repression. Both MYC and MYCN physically interacts with
PRC2 in mESCs. Indeed, thanks to biochemical approaches, we
demonstrated that MYC, together with MAX, interacts with the
three core component of PRC2 (Eed, Ezh2, and Suz12) and the
Aebp2 associated protein, through its conserved MBII motif
located in N-terminal TAD. Functional analysis revealed that
the MYC/PRC2-induced inhibition of developmental pathways
is required to maintain mESCs identity, as the knocking-down
of either Eed or Ezh2, leads to spontaneous differentiation of
MYC-dependent cells (Fagnocchi et al., 2016a). Altogether, these
findings demonstrate the global role of MYC in modulating the
differentiation potential of PSCs, in association with other TFs
and chromatin players.
In addition to MYC-mediated direct modulation, it indirectly
limits multi-lineage development of mESCs by transcriptionally
up-regulating all genes coding for the PRC2 and associated
factors (Neri et al., 2012). Furthermore, MYC is integrated
in a regulatory circuitry including multiple miRNAs, which
regulates expression of developmental-related genes in PSCs, as
commented in the next section.
MYC Integration with Non-coding RNAs
Regulatory Circuits
Non-coding RNAs (ncRNAs) are primary players in defining
PSCs identity (Greve et al., 2013; Rosa and Brivanlou, 2013;
Rosa and Ballarino, 2016). Among them, miRNAs are ∼20-base
long, processed and single stranded transcripts, which recognize
mRNAs by base pairing of a short “seed” sequence at their
5′end, thus leading to translational inhibition or degradation
of their targets (Fabian and Sonenberg, 2012). Evidence for
their role in pluripotency was first derived from mESCs lacking
either Dicer or Dgcr8, two key factors in miRNAs maturation.
Dicer- or Dgcr8-deficient mESCs are viable, but greatly impaired
in cell cycle, proliferation and unable to properly differentiate
(Kanellopoulou et al., 2005; Murchison et al., 2005; Wang et al.,
2007). A specific family of miRNAs, sharing the same AAGUGC
seed sequence, are conserved and majorly expressed among
PSCs, the so called ESC-specific cell-cycle regulating (ESCC)
miRNAs, which, together with ESCC-like miRNAs (shifted by
one base), comprise up to the 60% of all the miRNA population
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in PSCs. This family includes the clusters miR-290–295 and miR-
17–92b in mESCs and miR-302–367 in mEpiSCs and hESCs,
which, with exception of miR-17–92b, are not expressed in
somatic cells. Conversely, the let-7 family of miRNAs is post-
transciptionally repressed by the RNA binding protein LIN28,
which is specifically expressed in PSC and down-regulated upon
differentiation. (Greve et al., 2013; Rosa and Brivanlou, 2013).
Both families of miRNAs play a central function in regulation of
PSCs identity, underlined by the fact that their specific expression
is controlled by the core TRN and they integrate with the OSN
regulatory circuitry (Barroso-Deljesus et al., 2008; Card et al.,
2008; Marson et al., 2008). In addition, ESCC influence PSCs
by regulating their cell cycle, proliferation and differentiation
potential.
Long (> 200 nucleotides) non-coding RNAs (lncRNAs)
resemble protein-coding mRNAs and are usually spliced,
polyadenylated and possess a 5′cap. They can either act
as antisense transcripts, modulate the activity of chromatin
modifiers or serve as “sponges” for miRNAs, thus affecting their
activity (Guttman and Rinn, 2012). The signature of both mouse
and human ESCs have been deeply investigated, identifying
ESC-specific lncRNAs, which are partly targets of the core TFs
and whose levels decrease upon differentiation. Accordingly,
their down-regulation results in reduction of proliferation and
pluripotency markers expression, in parallel with induction of
lineage specific genes and differentiation (Dinger et al., 2008;
Guttman et al., 2009, 2010, 2011; Loewer et al., 2010; Sheik
Mohamed et al., 2010; Ng et al., 2012).
As mentioned in the previous sections, the role of MYC
in maintaining the PSC state is greatly interconnected with
regulation of ncRNAs (Figure 1, lower left panel). MYC
modulates both the counteracting ESCC and let-7 families of
miRNAs in PSCs. The ESCC miRNAs were defined with the
discovery that the miR-290–295 cluster was able to rescue the
Dgcr8−/−-induced defects on cell cycle and proliferation in
mESCs. The miR-290–295 favors the rapid transition from G1
to S phases and the peculiar cell cycle structure of PSCs, by
regulating the Cdk2-cyclin E complex. Importantly, miR-290–
295 acts downstream of MYC, which binds their promoters,
and is also involved in establishment of iPSCs, being able to
replace MYC in the reprogramming of mouse fibroblasts (Wang
et al., 2008; Judson et al., 2009). On the other hand, the let-7
family promotes differentiation and MYC, by transcriptionally
inducing the let-7 repressor LIN28, together with OSN, limits
its expression, thus supporting the PSCs state. Additionally,
in lymphoma cells, MYC directly binds let-7 and represses
it, while, in turn, mature let-7 inhibits MYC expression,
suggesting that these two factors are involved in a double-
negative feedback regulatory loop (Chang et al., 2008, 2009;
Marson et al., 2008; Melton et al., 2010; Zhong et al., 2010).
Importantly, the LIN28/let-7 axis has been also demonstrated
to be a central regulator of PSCs metabolism, in particular
as far as mitochondrial respiration is concerned (Shyh-Chang
and Daley, 2013; Psathas and Thomas-Tikhonenko, 2014),
suggesting MYC implication in the regulation of the Oxphos
metabolism critical to ESCs (Wang et al., 2009a; Zhang et al.,
2011; Carbognin et al., 2016). Furthermore, MYC induces
the miR-17–92 cluster in mESCs, which supports cell cycle
progression by the inhibition of controllers such as p21, cyclin
D1 and RB2. Accordingly, in MYC/MYCN dKO mESCs, the
miR-17–92 cluster is down-regulated and cells differentiate and
re-structure their cell cycle (Smith and Dalton, 2010; Smith
et al., 2010). MYC also directly activates miR-141, miR-200,
miR-338, and miR429, which repress differentiation pathways
(Lin et al., 2009a; Psathas and Thomas-Tikhonenko, 2014).
Importantly, up-regulation or inhibition of those classes of
miRNAs result in reduction or enhancement of differentiation of
mESCs, respectively, thus showing the functional importance of
this MYC/miRNAs integration in regulating the differentiation
potential of PSCs (Lin et al., 2009a). More recently, instead, MYC
has been demonstrated to indirectly limit the expression of miR-
24-3p/miR-24-2-5p, which inhibit OSN and MYC itself, acting
as anti-pluripotent miRNAs in mESCs. MYC and OSN activate
the protein arginine methyltransferase 7 (PRMT7), which, in
turn limits miR-24-3p/miR-24-2-5p expression (Lee et al., 2016).
Interestingly, MYC induces a stem-cell like miRNA signature
in aggressive hepatoblastomas, characterized by repression of
miR-100/let-7a-2/miR-125b-1 and activation of miR-371 (part of
the human homolog of murine miR-290-295), suggesting that
MYC-mediated regulation of miRNAs in PSCs is partly shared
with cancer cells and functionally relevant for tumorigenesis. In
support of this hypothesis, reversal of the MYC-driven miRNA
signature results into smaller tumor formation in mice (Chang
et al., 2008; Cairo et al., 2010). Finally, MYC has also been
implicated in the regulation of lncRNAs controlling pluripotency
and differentiation, either by directly binding their promoters or
by modulating their expression in collaboration with Dicer and
miRNAs, suggesting an even broader role of MYC in controlling
ncRNA in PSCs (Guttman et al., 2011; Zheng et al., 2014).
MYC and the Epigenetic State of PSCs
PSCs are endowed with unique chromatin and epigenetic
organization which allow their genome to respond to two
opposing needs: on one hand, it must be plastic to be ready
to enter developmental pathways; on the other side, it must
retain a cellular memory that specifies the PSCs state. To this
end, the PSC chromatin is highly dynamic and accessible, when
compared to committed cells, with large regions of transcribed
euchromatin and restricted PcG-repressed and heterochromatic
domains, marked with H3K27me3 and/or H3K9me3 (Brenner
et al., 2005; Meshorer and Misteli, 2006; Efroni et al., 2008;
Gaspar-Maia et al., 2011; Zhu et al., 2013; Tee and Reinberg,
2014). In addition, the most distinctive epigenetic feature of PSCs
is represented by the presence of bivalent domains, carrying
both activating H3K4me3 and repressing H3K27me3 histone
modifications and marking poised developmental-related genes,
ready to be activated in response to pro-differentiative stimuli
(Bernstein et al., 2006; Boyer et al., 2006; Lee et al., 2006;
Mikkelsen et al., 2007; Pan et al., 2007; Zhao et al., 2007).
MYC has been described to influence the global cellular
chromatin structure and to favor widespread active euchromatin,
by promoting hyperacetylation and modulating both H3K4me3
and H3K9ac, thus suggesting its role in defining the peculiar
chromatin state of PSCs (Knoepfler et al., 2006; Frye et al.,
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2007; Cotterman et al., 2008) (Figure 1, lower central panel). In
line with this idea, MYC null mESCs show a global epigenetic
remodeling, with a decrease of ∼70% of the active histone mark
H3K4me3, which significantly overlap with MYC binding sites
(Lin et al., 2009b). Mechanistically, MYC affects the chromatin
structure and the epigenetic landscapes in multiple ways. First
of all, it may transcriptionally modulate various chromatin
regulators. Indeed, components of the PRC1/2, of histone
acethyl- and methyltransferases complexes and of the Swi/Snf
remodeling factors were identified amongMYC targets in mESCs
(Kidder et al., 2008; Kim et al., 2008; Neri et al., 2012; Krepelova
et al., 2014). Secondly, MYC is well-documented to interact
with and recruit onto the chromatin several players implicated
in chromatin modifications and dynamics (Hann, 2014; Tu
et al., 2015). In particular, MYC interacts with various histone
acethyltransferase (HAT) complexes on their common targets,
suggesting its role in modulating the global histone H3 and H4
acetylation state of PSCs (Mcmahon et al., 2000; Frank et al., 2001,
2003; Fazzio et al., 2008; Lin et al., 2009b; Kim et al., 2010). More
recently, MYC has been found to co-localize on active genes with
two histone demethylases (HDMs), namely Kdm4b/c, required
for mESCs self-renewal, suggesting MYC implication also in
the regulation of the histone methylation state of PSCs (Das
et al., 2014). Furthermore, MYC may regulate transcriptional
repression in PSCs by physically interacting with epigenetic
regulators, such as Hdac1/3, Sin3A/B and Lsd1 (Kdm1a), which
are part of chromatin repressive complexes affecting both histone
acetylation and demethylation. (Liang et al., 2008; Wang et al.,
2009b; Smith et al., 2011; Hu and Wade, 2012; Mcdonel et al.,
2012; Amente et al., 2013; Garcia-Sanz et al., 2014). In line
with these evidences, in mESCs grown in MYC-dependency,
MYC interacts with PRC2 and this interaction is functionally
relevant in affecting the epigenome and the identity of mESCs.
Indeed, we demonstrated a global increment of both Suz12
binding and H3K27me3 deposition on promoters of bivalent
genes, compared to ESCs grown in presence of LIF. In addition,
MYC is able to directly recruit PRC2 on a subset of these bivalent
promoters, thus augmenting H3K27me3 and repressing gene
expression. Accordingly, impaired expression of either Eed or
Ezh2 is not compatible with maintenance of MYC-dependent
mESCs (Fagnocchi et al., 2016a).
MYC Modulation of Signaling Pathways
The TRN of PSCs is continuously targeted by downstream
effectors of environmental signaling pathways, which, therefore,
play a pivotal role in determining different pluripotent states.
As a consequence, propagation of diverse PSCs strictly relies on
well-defined growth conditions. Mouse ESCs were first derived
on mitotically inactive embryonic fibroblasts as feeders and in
presence of serum (Evans and Kaufman, 1981; Martin, 1981).
Thereafter, LIF and the bone morphogenetic protein 4 (BMP4)
were identified as key ingredients to propagate mESCs in feeder-
and serum-free conditions, thanks to their ability to activate
the Janus kinase–signal transducer and activator of transcription
3 (JAK/STAT3) pathway and repress developmental processes
through the SMAD/IDs cascade, respectively (Smith et al., 1988;
Williams et al., 1988; Ying et al., 2003). Nonetheless, LIF/serum
medium is commonly used as standard growing condition for
mESCs. Consequently, several other defined culturing media,
based on the utilization of chemical inhibitors, were developed
to propagate mESCs in a more “naïve” state of pluripotency
(also known as “ground state”), thus being more similar to
early pre-implantation PSCs of the ICM (Weinberger et al.,
2016). Among them, the two inhibitors (2i)/LIF medium
relies on the chemical repression of the MAPK/ERK kinases
signaling, achieved with PD0325901 (PD03), and concomitant
activation of the WNT pathway, through the use of CHIR99021
(CHIR), which inhibits GSK3β, thus stabilizing β-catenin, which
ultimately counteracts Tcf3 pro-differentiative activity in the
nucleus (Cole et al., 2008; Ying et al., 2008). Activation of
the MAPK/ERK cascade drives the transition toward primed
pluripotency and, therefore, both primed hESCs and murine
EpiSCs are cultured in presence of basic fibroblast growth factor
(FGF2), which activates MAPK/ERK, and Activin A, which
reinforces the transforming growth factor-β (TGFβ) signaling
(Thomson et al., 1998; Brons et al., 2007; Tesar et al., 2007).
More recently, several reports identified culture conditions to
propagate naïve hESCs, suggesting that this pluripotent state,
similarly to its murine counterpart, relies on ablation of the
MAPK/ERK pathway, activation of the BMP4, LIF, and WNT
signaling cascades and low activation of Activin A/TGFβ1
(Cartwright et al., 2005; Gafni et al., 2013; Theunissen et al.,
2014; Ware et al., 2014). Finally, to support the importance of
LIF, BMP4, and WNT signaling pathways in determining naïve
PSC identity, downstream effectors such as STAT3, SMAD1, and
TCF3, respectively, are hard-wired into the core TRN (Chen
et al., 2008; Cole et al., 2008; Ho et al., 2011).
MYC was first connected to the signaling pathways of PSCs,
when it was discovered to be a downstream target of the LIF/Stat3
cascade in mESCs (Cartwright et al., 2005) (Figure 1, upper right
panel). Upon LIF withdrawal, MYC levels decrease, due to both
lack of transcriptional activation and post-translational GSK3β-
dependent phosphorylation of threonine 58 (T58). Importantly,
sustained MYC activity, through activation of a MYC-ER fusion
protein, is able to circumvent LIF-dependency of mESCs,
suggesting that the LIF signaling importance for the pluripotent
state is, at least partially, due to MYC functions. Accordingly,
expression of a MYC dominant negative mutant leads to loss
of self-renewal and differentiation (Cartwright et al., 2005).
Consequently, MYC was also found to be involved in limiting the
MAPK/ERK signaling, thus sustaining pluripotency of mESCs
(Chappell et al., 2013).While ERK is known to stabilize MYC
protein, it has been shown that MYC and MAX transcriptionally
activate the dual specific phosphatases 2 and 7 (DUSP2/7),
which in turn bind and inactivate ERK1/2 through its de-
phosphorylation, leading to attenuation of the MAPK/ERK
activity. In accordance, loss of MYC leads to down-regulation
of DUSP2/7, stimulation of the MAPK/ERK pathway and
differentiation of mESCs (Sears et al., 2000; Chappell et al., 2013).
More recently, we demonstrated that MYC also sustains the
WNT pathway in mESCs and that this is required for MYC-
mediated maintenance of both self-renewal and pluripotency
(Fagnocchi et al., 2016a) (Figure 2A). Indeed, MYC leads to
an accumulation of nuclear β-catenin, while MYC/MYCN dKO
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FIGURE 2 | The MYC-driven self-reinforcing loop in ESCs. (A) MYC-dependent ESCs are maintained in presence of OHT, which activate MYC-ER, finally leading
to its nuclear localization. In the nucleus, MYC-ER stimulates a self-reinforcing positive feedback loop. Together with PRC2, MYC represses antagonist of the WNT
pathway, such as DKK and SFRP family members, thus resulting in activation of the WNT pathway. Consequently, active β-catenin translocates into the nucleus,
where, among its targets, it transcriptionally activates both myc and mycn. Endogenous MYC and MYCN, in turn, reinforce this mechanism by contributing to the
repression of WNT antagonists. The feedback positive loop is also sustained by the fact that MYC mediates the inhibition of the destruction complex (AXIN, APC,
(Continued)
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FIGURE 2 | Continued
GSK3β) function, resulting in reduction of GSK3β-dependent degradation of both MYC/MYCN and β-catenin (Fagnocchi et al., 2016a). (B) Role of MYC in sustaining
mESCs identity in MYC-dependent vs. 2i/LIF maintained cells. MYC-dependent cells rely on MYC for the concomitant down-regulation of MAPK/ERK and
up-regulation of WNT pathways (Chappell et al., 2013; Fagnocchi et al., 2016a). In addition, it also sustains proliferation by inducing the biosynthetic machinery. Once
MYC activity is lost, by either knocking down myc/mycn or by inactivating MYC-ER after short-term exposure to OHT, mESCs differentiate spontaneously as both the
proliferation and the maintenance of pluripotency gene expression are affected (Cartwright et al., 2005; Fagnocchi et al., 2016a). On the contrary, in 2i/LIF cultured
cells, chemical inhibitors bypass the role of MYC in modulating signaling pathways. Indeed, CHIR and PD activate and inhibit WNT and MAPK/ERK pathways,
respectively (Cole et al., 2008; Ying et al., 2008). Accordingly, MYC is less expressed in 2i/LIF mESCs (Marks et al., 2012). Nonetheless, MYC still have a key function
in 2i/LIF medium, as its deletion leads to impairment of the biosynthetic machinery and entrance of ESCs in a reversible dormant state (Scognamiglio et al., 2016).
Concomitantly, the pluripotency is not affected as chemical inhibitors still modulate signaling to the core TRN even in the absence of MYC. Solid green and red arrows
indicate high or low expression on nearby genes, respectively. Solid black arrows and flat lines indicate activation or repression, respectively. Red crosses indicate
inhibition of related functions.
mESCs show reduced amount of active β-catenin, respect
to wild type cells. Importantly, WNT pathway activation is
fundamental for MYC-mediated maintenance of mESCs, as
either knocking-down β-catenin or down-modulation of WNT
signaling with soluble inhibitors Dkk1 and Srfp1, result in loss of
stemness and spontaneous differentiation. Mechanistically, MYC
activates WNT signaling by transcriptionally activating receptors
and co-receptors (such as Fzd2, 3, and 7 and Lrp5), while
repressing antagonists of the pathway (such as Dkk and Sfrp
inhibitors family members), by directly recruiting PRC2 on their
promoters (Figure 2A). Of importance, endogenous myc and
mycn genes are targets of nuclear β-catenin and MYC-mediated
activation of the WNT pathway leads to their transcriptional
up-regulation, in a positive self-reinforcing regulatory loop
(Figure 2A) (Fagnocchi et al., 2016a).
Alltogether, these evidences collectively indicate that MYC
sustains PSC identity by inducing the WNT-pathway, while
limiting the MAPK/ERK signaling, resembling the activity of
chemical inhibitors of the 2i/LIF culturing medium (Figure 2B).
In accordance with this finding, in 2i/LIF mESCs the level of
MYC expression is lower compared to LIF/serum maintained
cells (Marks et al., 2012), suggesting that PD03 and CHIR
bypass the requirement of MYC to modulate signaling pathways
relevant for maintenance of pluripotency. While the chemicals
in 2i/LIF medium may render “ground state” mESCs partly
independent to MYC for their maintenance, they still require
its activity for their biosynthetic homeostasis. In fact, recent
findings show that pharmacological inhibition ofMYC activity or
MYC/MYCN concomitant deletion in mESCs cultured in 2i/LIF,
results in reduced RNA processing, ribosome biogenesis, protein
synthesis and, ultimately, arrest of proliferation and entering in a
dormant state, remindful of diapause balstocysts (Scognamiglio
et al., 2016). These conclusions suggest that MYC-mediated
control of the biosynthetic machinery in 2i/LIF cultured mESCs
is uncoupled from regulation of their pluripotency and rather
mostly implicated in their self-renewal potential (Figure 2B).
MYC in the Reprogramming of Somatic
Cells
Despite no data are available to prove a role for MYC in
establishing PSCs in vivo, the major evidence underlying its
function in the induction of the pluripotent state is its well-
known role in reprogramming of somatic cells. MYC is one of
the four transcription factors, together with OCT4, SOX2 and
KLF4 (OSKM), initially identified by Shinya Yamanaka’s lab as
sufficient to reprogram differentiated cells to iPSCs, both in mice
and humans (Takahashi and Yamanaka, 2006; Takahashi et al.,
2007). Since then, many different variations from the OSKM
cocktail have been used to improve the derivation of iPSCs
(Buganim et al., 2013; Theunissen and Jaenisch, 2014; Takahashi
and Yamanaka, 2016), nonetheless the reprogramming process
in absence of MYC is generally less efficient, both in terms
of the number of iPSCs and the time required to reach full
reprogrammed state (Nakagawa et al., 2008; Wernig et al., 2008).
Moreover, among the OSKM factors, MYC promotes the most
ESC-like transcriptional signature in fibroblasts, when expressed
alone (Sridharan et al., 2009).
Reprogramming is amulti-step event, throughout whichMYC
exerts its function since the early stages (Mikkelsen et al., 2008;
Sridharan et al., 2009; Soufi et al., 2012). In fact, MYC has been
proposed to mediate early global epigenetic changes, required
for the formation of euchromatin. Accordingly, two HDAC
inhibitors, the valproic acid (VPA) and trichostatin A (TSA),
enable reprogramming of both human and murine fibroblasts in
absence of MYC, indicating its role in controlling global histone
acetylation during generation of iPSCs (Huangfu et al., 2008;
Araki et al., 2011). These global epigenetic changes are reflected
in remodeling of gene expression patterns: MYC enhances early
reprogramming by repressing fibroblast specific genes more
efficiently than OCT4, SOX2, and KLF4 (OSK), while inducing
a PSC-like gene expression profile (Mikkelsen et al., 2008;
Sridharan et al., 2009). Of importance, MYC binds to enhancers
of pluripotency-related genes in early phases of de-differentiation
and there it increases the OSK engagement with chromatin and
its activating function. Nonetheless, it is noteworthy that MYC
cannot act as a “pioneer factor” and requires previous binding of
OSK to access the chromatin (Soufi et al., 2012).
Several factors can replace MYC function during
reprogramming, including metabolic modulators, miRNAs
and other pluripotent TFs, indicating that those mechanisms
by which MYC maintains PSCs, might also be relevant for
establishment of iPSCs (Yu et al., 2007; Judson et al., 2009;
Choi et al., 2011; Psathas and Thomas-Tikhonenko, 2014; Cao
et al., 2015; Ryall et al., 2015). In addition, the role of MYC in
modulating the cell cycle might be relevant for later stages of
reprogramming, as the typical cell cycle structure of PSCs is
not present in partially reprogrammed cells (Singh and Dalton,
2009).
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FIGURE 3 | MYC induces and epigenetic memory mechanism in ESCs. (A) Mouse ESCs can be maintained upon LIF withdrawal, providing activation of
MYC-ER, which leads to WNT pathway reinforcement, through PRC2-mediated repression of its antagonist, and induction of endogenous MYC and MYCN. If
MYC-ER remains activate for short term (e.g., 3–6 days), mESCs differentiate spontaneously once it is inactivated. On the contrary, long term activation of MYC-ER (at
least 12 days) leads to the stabilization of WNT reinforcement and concomitant induction of MYC/MYCN, even in the absence of the original stimulus (OHT), thanks to
a self-reinforcing loop. This epigenetic memory mechanism permits the maintenance of MYC-derived mESCs in absence of both LIF and MYC-ER activation
(Fagnocchi et al., 2016a). (B) The epigenetic memory of MYC-derived mESCs permits their reversion to a LIF-dependent state of pluripotency. LIF/serum maintained
mESCs are dependent on LIF/JAK/STAT cascade; hence LIF withdrawal leads to their differentiation. On the contrary, inhibition of both PRC2 activity and WNT
pathway do not affect their pluripotent state. Both MYC-dependent and MYC-derived mESCs are, instead, insensitive to LIF withdrawal, but rather strictly dependent
on the MYC/PRC2-mediated activation of WNT pathway. Importantly, culturing MYC-derived mESCs in LIF/serum medium reverts them back to a LIF-dependent but
PRC2/WNT-independent pluripotent state, underlying the epigenetic nature of the memory mechanism which permits their derivation. Accordingly, the expression of
downstream targets of both LIF and WNT pathways (SOCS3 and FZD7) is epigenetically controlled and switched between the different pluripotent states described
(Fagnocchi et al., 2016a). Solid green and red arrows indicate high or low expression on nearby genes/functions, respectively.
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Importantly, the clinical applications of iPSCs, are partly
hindered by the fact that MYC activation leads to oncogenic
transformation and animals derived from iPSCs induced by
OSKM frequently develop tumors (Okita et al., 2007).While poor
reprogramming is achieved without MYC (Nakagawa et al., 2008;
Wernig et al., 2008), the possibility to derive iPSCs with MYCL,
which posses less transformation capability, and, above all,
with transformation-defective MYC mutants, it is worth further
investigation to obtain clinically safe reprogrammed pluripotent
cells with high efficiency (Nakagawa et al., 2008, 2010).
MYC and Epigenetic Memory
The epigenetic memory can be defined as “a heritable change
in gene expression or behavior, that is induced by a previous
developmental or environmental stimulus and cannot be
explained by changes in the DNA sequence” (D’urso and
Brickner, 2014). During development, cells progressively reduce
their differentiation potential and acquire a committed cell
identity, in response to specific stimuli, which will be then
maintained long after the stimulus is passed (Ringrose and
Paro, 2004; Bonasio et al., 2010). This phenotypic stability
of differentiated cells relies on mechanisms which ensure the
transmission of epigenetic and, consequently, transcriptional
patterns. Accordingly, efficient reprogramming of committed
cells toward pluripotency requires the erasure of the existing
somatic epigenetic memory, which constitutes well-known
barriers to formation of iPSCs (Mikkelsen et al., 2008; Pasque
et al., 2012; Chen et al., 2013; Gaspar-Maia et al., 2013; Sridharan
et al., 2013; Nashun et al., 2015). Mechanistically, epigenetic
inheritance can be achieved by either self-propagating trans-
acting regulatory factors, maintained by feedback loops and
TF networks, or by cis-acting epigenetic signatures, such as
DNA methylation or histone modifications, which must be
maintained or re-established during and after cell division,
respectively (Bonasio et al., 2010; Moazed, 2011; Wang and
Higgins, 2013). Importantly, recent evidences indicate that
epigenetic memory is also maintained in ESCs, even though
with different mechanisms respect to somatic cells. Hence, the
pluripotent state is characterized by a highly stable epigenome
(Shipony et al., 2014).
We recently described a MYC-driven epigenetic memory
mechanism, which is able to maintain mESC identity (Fagnocchi
et al., 2016a). As mentioned above, MYC-dependent mESCs
rely on the activation of the WNT pathway to support their
stemness, which in turn induces expression of both endogenous
myc and mycn genes, establishing a positive feedback loop
(Figure 2A). Importantly, mESCs maintained for long-term in
MYC-dependency retain their identity, differentiation potential
and pluripotency, even after deactivation of MYC-ER. On the
contrary, mESCs which experienced short-term activation of
MYC-ER are not able to maintain the pluripotent state upon
MYC-ER deactivation and differentiate spontaneously. These
evidences indicate that the MYC-driven self-reinforcing circuit,
installed during MYC-dependency, is able to sustain PSCs in
the absence of the instructing stimulus. In accordance, mESCs
derived after MYC-ER deactivation (MYC-derived) possess a
transcriptional program conserved with MYC-dependent cells
and show activation of the WNT pathway, which is achieved
by the endogenous MYC proteins that recruit PRC2 on WNT
antagonists (Figure 3A). By definition, epigenetic regulatory
mechanisms must be reversible, as they are not dictated by
changes in DNA (Bonasio et al., 2010). In agreement with this,
MYC-derived cells can be reprogrammed to a LIF-dependent
state of pluripotency. Indeed, MYC-derived mESCs, as their
parental MYC-maintained counterpart, are strictly dependent
on WNT pathway activation and the PRC2 activity, while
mESCs cultured in LIF/serum only depend on the JAK/STAT3
signaling (Figure 3B). By culturing MYC-derived cells in
LIF/serum containing medium, they undergo a reprogramming
process which render them LIF-dependent but WNT- and
PRC2-independent. Of importance, this is accompanied by an
epigenetic reprogramming in whichWNT pathway related genes
(e.g., Fzd7) switch from an active state, marked by H3K4me3
deposition on their promoter, to transcriptional repression,
underlined by gaining of the H3K27me3 repressive mark. Vice
versa, downstream effectors of the LIF/JAK/STAT3 cascade
(e.g., SOCS3) re-acquire transcriptional activation, after having
been repressed in both MYC-dependent and MYC-derived cells
(Figure 3B). Altogether, these evidences demonstrate that MYC
is able to induce a reversible epigenetic memory, which is
sufficient to sustain PSCs.
CONCLUSIONS AND IMPLICATIONS
Since MYC was first implicated in maintaining mESCs more
than 10 years ago (Cartwright et al., 2005), its central role
in integrating complex regulatory networks in PSCs has been
tremendously reinforced and deepened. Its ability to bind specific
targets and to possibly invade less specific genomic regions (Lin
et al., 2012; Nie et al., 2012; Sabo et al., 2014; Walz et al.,
2014), together with its plethora of interactions with other TFs
and chromatin players (Smith et al., 2011; Tu et al., 2015),
renders MYC a central hub involved in many aspects of the PSC
regulation. For the same reason, the therapeutic implications
of unraveling the MYC-mediated molecular mechanisms, which
induce and maintain the pluripotent state, are self-evident.
Immediately after their first derivation (Takahashi et al., 2007),
human iPSCs were generated from patients affected from a
variety of pathologies (Dimos et al., 2008; Park et al., 2008). These
patients-derived iPSCs hold the potential to generate disease
models, which overcome the limits imposed by using other
mammal models, such as the differences at the genomic level,
in embryonic development and organ functions. Both human
ESCs, either carrying spontaneous chromosomal aberrations or
genetically engineered, and iPSCs from patients are now used as
disease models, whose applications range from identification of
the pathological molecular mechanisms, to drug discovery and
toxicity testing (Zeltner and Studer, 2015; Avior et al., 2016).
Furthermore, the use of patient-specific PSCs holds promises to
move medical research and therapies toward more personalized
approaches. Accordingly, hESCs/iPSCs may be eventually used
in autologous cell replacement therapies and PSC-derivatives
are now being evaluated in ongoing clinical trials for their
Frontiers in Cell and Developmental Biology | www.frontiersin.org 13 February 2017 | Volume 5 | Article 7
Fagnocchi and Zippo MYC Roles in Pluripotency
safety and therapeutic benefits (Trounson and Dewitt, 2016).
Finally, iPSCs can also be used as models for tumorigenesis
(Kim and Zaret, 2015; Laplane et al., 2015). Indeed, human cells
from a variety of cancers have been reprogrammed to iPSCs,
in which the pluripotency state can partially suppress cancer
features, by restoring the differentiation potential while reducing
tumorigenicity. Nonetheless, these cancer-derived iPSCs can re-
acquire the aggressive phenotype, once differentiated toward
the tissue of origin, therefore representing a powerful tool to
study early steps of oncogenesis, its progression, the markers and
pathways involved and the response to therapeutics (Kim and
Zaret, 2015; Laplane et al., 2015). In this regard, the role of MYC
in controlling the regulatory networks of PSCs is particularly
important as it is found up-regulated in up to the 70% of all
humanmalignancies and, as commented in the previous sections,
some of its regulated functions are shared between cancer and
PSC, opening the possibility for therapeutic targeting (Dang,
2012; Ciriello et al., 2013; Gabay et al., 2014).
While the feasibility of generating PSC-based models
and deriving cells for regenerative medicine have been
often reported, much additional work will be required to
evaluate the impact of those applications in treating multiple
diseases.
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